Compare FOR & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | NNNN |
|---|---|---|
| Founded | 2005 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2007 | N/A |
| Metric | FOR | NNNN |
|---|---|---|
| Price | $24.98 | $25.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $31.75 | N/A |
| AVG Volume (30 Days) | ★ 108.9K | 21.8K |
| Earning Date | 04-21-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,662,400,000.00 | N/A |
| Revenue This Year | $0.52 | N/A |
| Revenue Next Year | $7.72 | N/A |
| P/E Ratio | ★ $81.50 | $446.57 |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $18.00 | $5.91 |
| 52 Week High | $30.74 | $55.65 |
| Indicator | FOR | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 41.62 | 55.57 |
| Support Level | $24.20 | $19.53 |
| Resistance Level | $26.06 | $30.70 |
| Average True Range (ATR) | 0.79 | 2.17 |
| MACD | 0.01 | 0.53 |
| Stochastic Oscillator | 38.60 | 70.37 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.